Imexpharm（IMP）株式概要イメックスファーム株式会社は、ベトナム国内および国際的な医薬品の製造、加工、取引、輸出入を行っています。 詳細IMP ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長1/6過去の実績3/6財務の健全性6/6配当金0/6報酬当社が推定した公正価値より75.3%で取引されている 収益は年間17.2%増加すると予測されています 過去5年間の収益は年間13.6%増加しました。 リスク分析リスクチェックの結果、IMP 、リスクは検出されなかった。すべてのリスクチェックを見るIMP Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₫Current Price₫45.50k3.2% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture04t2016201920222025202620282031Revenue ₫3.9tEarnings ₫510.6bAdvancedSet Fair ValueView all narrativesImexpharm Corporation 競合他社Ha Tay Pharmaceutical JSCSymbol: HNX:DHTMarket cap: ₫6.0tBinh Dinh Pharmaceutical and Medical EquipmentSymbol: HOSE:DBDMarket cap: ₫4.7tDHG PharmaceuticalSymbol: HOSE:DHGMarket cap: ₫12.2tTraphacoSymbol: HOSE:TRAMarket cap: ₫3.2t価格と性能株価の高値、安値、推移の概要Imexpharm過去の株価現在の株価₫45,500.0052週高値₫57,000.0052週安値₫45,000.00ベータ0.391ヶ月の変化-2.47%3ヶ月変化-16.36%1年変化-11.82%3年間の変化80.28%5年間の変化30.57%IPOからの変化116.06%最新ニュースお知らせ • Apr 30Livzon Pharmaceutical Group Inc. (SZSE:000513) acquired 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion.Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 77.94% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6.9 trillion on May 22, 2025. A cash consideration of VND 5.73 trillion will be paid by Livzon Pharmaceutical Group Inc. As part of consideration, VND 5.73 trillion is paid towards common equity of Imexpharm Corporation. The Acquisition will be funded by the Group’s internal resources. The Acquisition will lay a solid foundation for the Group’s further expansion into overseas markets, supporting its long-term strategy of internationalization and sustainable development in the pharmaceutical sector. On December 29, 2025, the parties signed Amendment Agreement to Framework Agreement agreeing to increase the maximum number of shares to be acquired through this proposed public tender offer to 120,059,970 shares, 77.94% stake, in accordance with Imexpharm Corporation’s foreign ownership cap requirements, and the Company will pay a maximum of VND 6,891,442,278,000. As of March 6, 2026 Livzon Pharmaceutical Group has officially received approval from the State Securities Commission of Vietnam. This allows them to proceed with a voluntary public tender offer for IMP shares. The transaction is subject to approval by merger control clearance, Permissible Foreign Ownership Limit, Absence of Material Adverse Change and other Customary Conditions. The number of shares intended to be sold by the Target Company’s shareholders does not reach the minimum threshold of 99,839,990 shares, representing 64.81% of the Target Company’s charter capital. The expected completion of the transaction is the date falling nine (9) months from the date of the Agreement. The transaction has been approved by the board of directors of Livzon Pharmaceutical Group Inc. Ernst & Young Vietnam Limited acted as due diligence provider to SK Investment Vina III Pte Ltd. Livzon Pharmaceutical Group Inc. (SZSE:000513) completed the acquisition of 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion on April 29, 2026. Shareholders of Livzon Pharmaceutical Group Inc. have reached the minimum threshold of 99,839,990 shares, representing 64.81% of Imexpharm Corporation.Reported Earnings • Mar 28Full year 2025 earnings: EPS in line with expectations, revenues disappointFull year 2025 results: EPS: ₫1,976 (up from ₫1,791 in FY 2024). Revenue: ₫2.44t (up 11% from FY 2024). Net income: ₫304.4b (up 10% from FY 2024). Profit margin: 13% (in line with FY 2024). Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 9.8% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 09Imexpharm Corporation, Annual General Meeting, Apr 22, 2026Imexpharm Corporation, Annual General Meeting, Apr 22, 2026.Reported Earnings • Jan 22Full year 2025 earnings: EPS in line with expectations, revenues disappointFull year 2025 results: EPS: ₫1,976 (up from ₫1,932 in FY 2024). Revenue: ₫2.44t (up 11% from FY 2024). Net income: ₫304.4b (up 2.3% from FY 2024). Profit margin: 13% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Oct 23Third quarter 2025 earnings released: EPS: ₫429 (vs ₫436 in 3Q 2024)Third quarter 2025 results: EPS: ₫429. Revenue: ₫573.6b (up 5.3% from 3Q 2024). Net income: ₫76.9b (up 6.2% from 3Q 2024). Profit margin: 13% (in line with 3Q 2024). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia.Upcoming Dividend • Jun 02Upcoming dividend of ₫500 per shareEligible shareholders must have bought the stock before 09 June 2025. Payment date: 09 July 2025. Payout ratio is a comfortable 30% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Vietnamese dividend payers (8.0%). Lower than average of industry peers (5.6%).最新情報をもっと見るRecent updatesお知らせ • Apr 30Livzon Pharmaceutical Group Inc. (SZSE:000513) acquired 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion.Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 77.94% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6.9 trillion on May 22, 2025. A cash consideration of VND 5.73 trillion will be paid by Livzon Pharmaceutical Group Inc. As part of consideration, VND 5.73 trillion is paid towards common equity of Imexpharm Corporation. The Acquisition will be funded by the Group’s internal resources. The Acquisition will lay a solid foundation for the Group’s further expansion into overseas markets, supporting its long-term strategy of internationalization and sustainable development in the pharmaceutical sector. On December 29, 2025, the parties signed Amendment Agreement to Framework Agreement agreeing to increase the maximum number of shares to be acquired through this proposed public tender offer to 120,059,970 shares, 77.94% stake, in accordance with Imexpharm Corporation’s foreign ownership cap requirements, and the Company will pay a maximum of VND 6,891,442,278,000. As of March 6, 2026 Livzon Pharmaceutical Group has officially received approval from the State Securities Commission of Vietnam. This allows them to proceed with a voluntary public tender offer for IMP shares. The transaction is subject to approval by merger control clearance, Permissible Foreign Ownership Limit, Absence of Material Adverse Change and other Customary Conditions. The number of shares intended to be sold by the Target Company’s shareholders does not reach the minimum threshold of 99,839,990 shares, representing 64.81% of the Target Company’s charter capital. The expected completion of the transaction is the date falling nine (9) months from the date of the Agreement. The transaction has been approved by the board of directors of Livzon Pharmaceutical Group Inc. Ernst & Young Vietnam Limited acted as due diligence provider to SK Investment Vina III Pte Ltd. Livzon Pharmaceutical Group Inc. (SZSE:000513) completed the acquisition of 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion on April 29, 2026. Shareholders of Livzon Pharmaceutical Group Inc. have reached the minimum threshold of 99,839,990 shares, representing 64.81% of Imexpharm Corporation.Reported Earnings • Mar 28Full year 2025 earnings: EPS in line with expectations, revenues disappointFull year 2025 results: EPS: ₫1,976 (up from ₫1,791 in FY 2024). Revenue: ₫2.44t (up 11% from FY 2024). Net income: ₫304.4b (up 10% from FY 2024). Profit margin: 13% (in line with FY 2024). Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 9.8% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 09Imexpharm Corporation, Annual General Meeting, Apr 22, 2026Imexpharm Corporation, Annual General Meeting, Apr 22, 2026.Reported Earnings • Jan 22Full year 2025 earnings: EPS in line with expectations, revenues disappointFull year 2025 results: EPS: ₫1,976 (up from ₫1,932 in FY 2024). Revenue: ₫2.44t (up 11% from FY 2024). Net income: ₫304.4b (up 2.3% from FY 2024). Profit margin: 13% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Oct 23Third quarter 2025 earnings released: EPS: ₫429 (vs ₫436 in 3Q 2024)Third quarter 2025 results: EPS: ₫429. Revenue: ₫573.6b (up 5.3% from 3Q 2024). Net income: ₫76.9b (up 6.2% from 3Q 2024). Profit margin: 13% (in line with 3Q 2024). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia.Upcoming Dividend • Jun 02Upcoming dividend of ₫500 per shareEligible shareholders must have bought the stock before 09 June 2025. Payment date: 09 July 2025. Payout ratio is a comfortable 30% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Vietnamese dividend payers (8.0%). Lower than average of industry peers (5.6%).お知らせ • May 22Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 64.81% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd. and others for VND 5.7 trillion.Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 64.81% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd. and others for VND 5.7 trillion on May 22, 2025. A cash consideration of VND 5.73 trillion will be paid by Livzon Pharmaceutical Group Inc. As part of consideration, VND 5.73 trillion is paid towards common equity of Imexpharm Corporation. The Acquisition will be funded by the Group’s internal resources. The Acquisition will lay a solid foundation for the Group’s further expansion into overseas markets, supporting its long-term strategy of internationalization and sustainable development in the pharmaceutical sector. The transaction is subject to approval by merger control clearance, Permissible Foreign Ownership Limit, Absence of Material Adverse Change and other Customary Conditions. The expected completion of the transaction is the date falling nine (9) months from the date of the Agreement.Reported Earnings • Apr 19First quarter 2025 earnings released: EPS: ₫448 (vs ₫371 in 1Q 2024)First quarter 2025 results: EPS: ₫448 (up from ₫371 in 1Q 2024). Revenue: ₫594.1b (up 21% from 1Q 2024). Net income: ₫74.5b (up 42% from 1Q 2024). Profit margin: 13% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.New Risk • Mar 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Vietnamese stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Mar 05Imexpharm Corporation, Annual General Meeting, Apr 25, 2025Imexpharm Corporation, Annual General Meeting, Apr 25, 2025.Reported Earnings • Jan 24Full year 2024 earnings released: EPS: ₫1,932 (vs ₫1,653 in FY 2023)Full year 2024 results: EPS: ₫1,932 (up from ₫1,653 in FY 2023). Revenue: ₫2.21t (up 11% from FY 2023). Net income: ₫320.9b (up 26% from FY 2023). Profit margin: 15% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 29Imexpharm Corporation Appoints Sung Min Woo as Chairperson of the Nomination and Compensation Committee Under the Board of DirectorsImexpharm Corporation announced the Board of Directors' Decision No. 08/2024/QÐ-HÐQT-IMP dated November 27, 2024, regarding the appointment of Mr. Sung Min Woo, Chairperson of the Board of Directors, as the Chairperson of the Nomination and Compensation Committee under the Board of Directors.Reported Earnings • Oct 22Third quarter 2024 earnings released: EPS: ₫436 (vs ₫404 in 3Q 2023)Third quarter 2024 results: EPS: ₫436 (up from ₫404 in 3Q 2023). Revenue: ₫544.7b (up 17% from 3Q 2023). Net income: ₫72.4b (up 3.9% from 3Q 2023). Profit margin: 13% (down from 15% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 10% per year.New Risk • Sep 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Vietnamese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Price Target Changed • Aug 23Price target increased by 9.2% to ₫78,485Up from ₫71,861, the current price target is an average from 3 analysts. New target price is 8.1% below last closing price of ₫85,400. Stock is up 46% over the past year. The company is forecast to post earnings per share of ₫4,012 for next year compared to ₫3,307 last year.Reported Earnings • Jul 23Second quarter 2024 earnings released: EPS: ₫794 (vs ₫851 in 2Q 2023)Second quarter 2024 results: EPS: ₫794 (down from ₫851 in 2Q 2023). Revenue: ₫517.2b (up 18% from 2Q 2023). Net income: ₫65.9b (down 4.8% from 2Q 2023). Profit margin: 13% (down from 16% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 9.4% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 10% per year.Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₫81,600, the stock trades at a trailing P/E ratio of 26.1x. Average forward P/E is 19x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₫73,716 per share.Upcoming Dividend • Jul 05Upcoming dividend of ₫1,000 per shareEligible shareholders must have bought the stock before 11 July 2024. Payment date: 23 July 2024. Payout ratio is a comfortable 27% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Vietnamese dividend payers (8.3%). Lower than average of industry peers (3.4%).お知らせ • Jul 04Imexpharm Corporation Announces Dividend for the Year 2023, Payable on July 23, 2024Imexpharm Corporation announced Dividend Payout ratio 10% share based on par value (1 share will receive 1,000 VND) for the year 2023. Payment time is July 23, 2024. Ex-right date: July 11, 2024. Record date: July 12, 2024.Reported Earnings • Apr 23First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: ₫491.1b (up 2.5% from 1Q 2023). Net income: ₫61.9b (up 14% from 1Q 2023). Profit margin: 13% (up from 11% in 1Q 2023).お知らせ • Mar 27Imexpharm Corporation, Annual General Meeting, Apr 26, 2024Imexpharm Corporation, Annual General Meeting, Apr 26, 2024, at 07:45 SE Asia Standard Time. Location: 5th Floor. Hilton Saigon Hotel, No. 11 Me Unh Square, Ben Nghe Ward, District 1, Ho Chi Minh City VietnamReported Earnings • Jan 21Full year 2023 earnings released: EPS: ₫3,637 (vs ₫2,810 in FY 2022)Full year 2023 results: EPS: ₫3,637 (up from ₫2,810 in FY 2022). Revenue: ₫1.99t (up 21% from FY 2022). Net income: ₫299.6b (up 52% from FY 2022). Profit margin: 15% (up from 12% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.お知らせ • Dec 20Imexpharm Corporation Approves Election of Hoang Duc Hung as an Independent Member of the Board of DirectorsImexpharm Corporation announced that at the General Meeting of Shareholders held on December 19, 2023, approved election of Mr. Hoang Duc Hung as an independent member of the Board of Directors of the Company for the term 2023-2027. Year of birth: 1973, Literacy: Postgraduate. Professional level: Master of International Finance (Oxford Brookes), CIA (IIA), FCCA, FCPA Aust, VACPA. Nationality: Vietnamese. Employment history: From 11/1994 to 06/2014: Audit Director, Leadership of Advisory Services Division, Leadership of the Government and Public Sector Clients Division, Ernst & Young (EY) Vietnam Limited. From 07/2014 to 09/2016: International Consultant - World Bank, supporting the Ministry of Finance in building the Internal audit framework in Vietnam. From 10/2016 to 11/2020: Deputy General Director - PwC Vietnam Limited. From 12/2020 to present: Chairman of the BOD - of CGS Vietnam Governance Consultancy Joint Stock Company; Board Member - Gentis Testing Service Joint Stock Company. From 09/2022 to present: Vice President, Executive Committee Member of Vietnam Independent Directors Association; President of Institute of Internal Auditors Vietnam - IIA Vietnam Chapter. Current positions at other Organizations: President of Institute of Internal Auditors Vietnam - IIA Vietnam Chapter. Vice President, Executive Committee Member of Vietnam Independent Directors Association. Chairman of CGS Vietnam Governance Consultancy Joint Stock Company. Members of BOD of Gentis Testing Service Joint Stock Company. Independent BOD Member of No Va Land Investment Group Corporation.Reported Earnings • Oct 21Third quarter 2023 earnings released: EPS: ₫889 (vs ₫817 in 3Q 2022)Third quarter 2023 results: EPS: ₫889 (up from ₫817 in 3Q 2022). Revenue: ₫466.9b (up 12% from 3Q 2022). Net income: ₫69.7b (up 25% from 3Q 2022). Profit margin: 15% (up from 13% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 11% per year and the company’s share price has also increased by 11% per year.Upcoming Dividend • Sep 28Upcoming dividend of ₫1,000 per share at 1.5% yieldEligible shareholders must have bought the stock before 05 October 2023. Payment date: 20 October 2023. Trailing yield: 1.5%. Lower than top quartile of Vietnamese dividend payers (8.8%). Lower than average of industry peers (3.2%).お知らせ • Sep 19Imexpharm Corporation Announces Dividend, Payable on October 20, 2023Imexpharm Corporation announced Dividend Payout ratio 10% share based on par value (1 share will receive 1,000 VND). Payment time is October 20, 2023.Upcoming Dividend • Aug 31Upcoming dividend of ₫1,000 per share at 1.5% yieldEligible shareholders must have bought the stock before 07 September 2023. Payment date: 06 October 2023. Trailing yield: 1.5%. Lower than top quartile of Vietnamese dividend payers (8.6%). Lower than average of industry peers (3.2%).Price Target Changed • Aug 17Price target increased by 14% to ₫84,000Up from ₫73,633, the current price target is provided by 1 analyst. New target price is 20% above last closing price of ₫69,800. Stock is up 10% over the past year. The company is forecast to post earnings per share of ₫4,858 for next year compared to ₫2,951 last year.Reported Earnings • Jul 20Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: ₫439.7b (up 24% from 2Q 2022). Net income: ₫79.7b (up 66% from 2Q 2022). Profit margin: 18% (up from 14% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia.お知らせ • May 07Imexpharm Corporation Appoints Chun Chaerhan as Chairperson of the Board of DirectorsImexpharm Corporation at its board meeting held on April 28, 2023, approved the election of Ms. Chun Chaerhan to hold the position of Chairperson of the Board of Directors of the company. The Chairperson of the Board of Directors is responsible for performing her obligations and powers in accordance with the Company's Charter, the Internal Regulations on Governance, the Operating Rules of the Board of Directors, and the provisions of law.Reported Earnings • Mar 28Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: ₫2,951 (up from ₫2,603 in FY 2021). Revenue: ₫1.64t (up 30% from FY 2021). Net income: ₫196.7b (up 13% from FY 2021). Profit margin: 12% (down from 14% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 7.4%. Earnings per share (EPS) also surpassed analyst estimates by 1.5%. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 14% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Jan 19Full year 2022 earnings released: EPS: ₫3,495 (vs ₫2,600 in FY 2021)Full year 2022 results: EPS: ₫3,495 (up from ₫2,600 in FY 2021). Revenue: ₫1.64t (up 30% from FY 2021). Net income: ₫234.0b (up 35% from FY 2021). Profit margin: 14% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 14% per year.Price Target Changed • Jan 04Price target decreased to ₫66,600Down from ₫73,633, the current price target is an average from 2 analysts. New target price is 11% above last closing price of ₫60,200. Stock is down 21% over the past year. The company is forecast to post earnings per share of ₫3,444 for next year compared to ₫2,600 last year.Valuation Update With 7 Day Price Move • Dec 02Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₫62,500, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 63% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₫56,442 per share.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Hung Truong was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 21Third quarter 2022 earnings released: EPS: ₫858 (vs ₫413 in 3Q 2021)Third quarter 2022 results: EPS: ₫858 (up from ₫413 in 3Q 2021). Revenue: ₫417.8b (up 63% from 3Q 2021). Net income: ₫55.8b (up 78% from 3Q 2021). Profit margin: 13% (up from 12% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 25Imexpharm Corporation announced that it has received funding from SK Group Ltd.Imexpharm Corporation announced that it has received a round of funding from SK Group Ltd. on August 25, 2022.Reported Earnings • Jul 23Second quarter 2022 earnings released: EPS: ₫615 (vs ₫684 in 2Q 2021)Second quarter 2022 results: EPS: ₫615. Revenue: ₫354.5b (up 12% from 2Q 2021). Net income: ₫46.6b (up 2.3% from 2Q 2021). Profit margin: 13% (down from 14% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 25%, compared to a 24% growth forecast for the industry in Vietnam.Price Target Changed • Jul 14Price target increased to ₫79,000Up from ₫73,633, the current price target is an average from 2 analysts. New target price is 27% above last closing price of ₫62,000. Stock is down 15% over the past year. The company is forecast to post earnings per share of ₫3,069 for next year compared to ₫2,600 last year.お知らせ • Jun 01Imexpharm Corporation Announces Personnel ChangeOn May 25, 2022, Imexpharm Corporation announces the appointment of Mrs. Han Thi Khanh Vinh – member of BOD as Head of Internal Audit Subcommittee and Risk Management Department to replace Mr. Tran Anh Tuan from May 24, 2022.Upcoming Dividend • May 18Upcoming dividend of ₫1,500 per shareEligible shareholders must have bought the stock before 25 May 2022. Payment date: 24 June 2022. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of Vietnamese dividend payers (7.3%). Lower than average of industry peers (3.6%).お知らせ • May 14Imexpharm Corporation Announces Cash Dividend for 2021, Payable on June 24, 2022Imexpharm Corporation announced to pay cash dividend for 2021. Exercise ratio: 15.0% (VND 1,500/share). Payment date: June 24, 2022. Ex-right date: May 25, 2022. Record date: May 26, 2022.Board Change • Apr 27No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 3 experienced directors. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Hung Truong was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Mar 13Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: EPS: ₫2,600 (down from ₫2,773 in FY 2020). Revenue: ₫1.27t (down 7.5% from FY 2020). Net income: ₫173.4b (down 3.5% from FY 2020). Profit margin: 14% (in line with FY 2020). Revenue missed analyst estimates by 9.2%. Earnings per share (EPS) also missed analyst estimates by 12%. Over the next year, revenue is forecast to grow 19%, compared to a 19% growth forecast for the pharmaceuticals industry in Vietnam. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Oct 21Third quarter 2021 earnings released: EPS ₫413 (vs ₫478 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₫256.2b (down 12% from 3Q 2020). Net income: ₫31.3b (down 39% from 3Q 2020). Profit margin: 12% (down from 18% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.Price Target Changed • Aug 10Price target increased to ₫75,300Up from ₫68,400, the current price target is an average from 3 analysts. New target price is 5.5% above last closing price of ₫71,400. Stock is up 63% over the past year.Reported Earnings • Jul 23Second quarter 2021 earnings released: EPS ₫651 (vs ₫1,180 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₫317.4b (up 9.9% from 2Q 2020). Net income: ₫49.3b (up 36% from 2Q 2020). Profit margin: 16% (up from 13% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 22% per year.Upcoming Dividend • Jun 16Upcoming dividend of ₫1,500 per shareEligible shareholders must have bought the stock before 23 June 2021. Payment date: 16 July 2021. Trailing yield: 2.0%. Lower than top quartile of Vietnamese dividend payers (7.5%). Lower than average of industry peers (3.8%).Reported Earnings • Apr 24First quarter 2021 earnings released: EPS ₫615 (vs ₫564 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: ₫296.4b (down 2.4% from 1Q 2020). Net income: ₫41.0b (up 13% from 1Q 2020). Profit margin: 14% (up from 12% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 19% per year and the company’s share price has also increased by 19% per year.Reported Earnings • Mar 20Full year 2020 earnings released: EPS ₫2,773 (vs ₫2,225 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: ₫1.37t (down 2.4% from FY 2019). Net income: ₫179.7b (up 26% from FY 2019). Profit margin: 13% (up from 10% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 20% per year.Is New 90 Day High Low • Feb 18New 90-day high: ₫60,600The company is up 17% from its price of ₫52,000 on 20 November 2020. The Vietnamese market is also up 17% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫26,735 per share.Analyst Estimate Surprise Post Earnings • Jan 23Revenue and earnings miss expectationsRevenue missed analyst estimates by 3.2%. Earnings per share (EPS) also missed analyst estimates by 4.4%. Over the next year, revenue is forecast to grow 39%, compared to a 247% growth forecast for the Pharmaceuticals industry in Vietnam.Reported Earnings • Jan 20Full year 2020 earnings released: EPS ₫2,773The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: ₫1.37t (down 2.4% from FY 2019). Net income: ₫209.7b (up 47% from FY 2019). Profit margin: 15% (up from 10% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Jan 04New 90-day high: ₫58,000The company is up 21% from its price of ₫48,000 on 06 October 2020. The Vietnamese market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫23,764 per share.Price Target Changed • Dec 23Price target raised to ₫57,910Up from ₫52,663, the current price target is an average from 2 analysts. The new target price is close to the current share price of ₫56,000. As of last close, the stock is up 49% over the past year.Is New 90 Day High Low • Dec 14New 90-day high: ₫56,800The company is up 15% from its price of ₫49,500 on 15 September 2020. The Vietnamese market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫20,200 per share.Is New 90 Day High Low • Nov 25New 90-day high: ₫54,900The company is up 14% from its price of ₫48,100 on 27 August 2020. The Vietnamese market is also up 14% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫16,865 per share.Is New 90 Day High Low • Nov 02New 90-day high: ₫49,550The company is up 11% from its price of ₫44,500 on 04 August 2020. The Vietnamese market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫16,865 per share.Reported Earnings • Oct 21Third quarter earnings releasedOver the last 12 months the company has reported total profits of ₫180.0b, up 32% from the prior year. Total revenue was ₫1.40t over the last 12 months, up 11% from the prior year.株主還元IMPVN PharmaceuticalsVN 市場7D-1.4%-0.1%1.9%1Y-11.8%-3.2%34.5%株主還元を見る業界別リターン: IMP過去 1 年間で-3.2 % の収益を上げたVN Pharmaceuticals業界を下回りました。リターン対市場: IMPは、過去 1 年間で34.5 % のリターンを上げたVN市場を下回りました。価格変動Is IMP's price volatile compared to industry and market?IMP volatilityIMP Average Weekly Movement3.7%Pharmaceuticals Industry Average Movement4.0%Market Average Movement4.2%10% most volatile stocks in VN Market7.0%10% least volatile stocks in VN Market2.2%安定した株価: IMP 、 VN市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: IMPの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19971,444Dao Tranwww.imexpharm.comImexpharm社はベトナム国内外において医薬品の製造、加工、取引、輸出入を行っている。同社の製品には、経口・注射用抗生物質、消化器系、中枢神経系、循環器系、糖尿病、眼科、筋骨格系、呼吸器系、鎮痛・抗炎症・解熱剤、抗ヒスタミン剤、抗アレルギー剤、抗寄生虫剤、外用薬、ビタミン・ミネラル、サプリメントなどがある。また、医療機器・消耗品、化学薬品、医薬品製造・包装用資材、人体への滅菌・消毒用薬品の輸出入も行っている。同社は1977年に設立され、ベトナムのカオランに本社を置いている。もっと見るImexpharm Corporation 基礎のまとめImexpharm の収益と売上を時価総額と比較するとどうか。IMP 基礎統計学時価総額₫7.01t収益（TTM）₫311.12b売上高(TTM)₫2.39t22.5xPER（株価収益率2.9xP/SレシオIMP は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計IMP 損益計算書（TTM）収益₫2.39t売上原価₫1.25t売上総利益₫1.14tその他の費用₫831.71b収益₫311.12b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）2.02kグロス・マージン47.75%純利益率13.00%有利子負債／自己資本比率8.4%IMP の長期的なパフォーマンスは？過去の実績と比較を見る配当金1.1%現在の配当利回り25%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/21 22:06終値2026/06/19 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Imexpharm Corporation 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関null nullFPT SecuritiesQuan CaoViet Dragon Securities Corporation
お知らせ • Apr 30Livzon Pharmaceutical Group Inc. (SZSE:000513) acquired 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion.Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 77.94% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6.9 trillion on May 22, 2025. A cash consideration of VND 5.73 trillion will be paid by Livzon Pharmaceutical Group Inc. As part of consideration, VND 5.73 trillion is paid towards common equity of Imexpharm Corporation. The Acquisition will be funded by the Group’s internal resources. The Acquisition will lay a solid foundation for the Group’s further expansion into overseas markets, supporting its long-term strategy of internationalization and sustainable development in the pharmaceutical sector. On December 29, 2025, the parties signed Amendment Agreement to Framework Agreement agreeing to increase the maximum number of shares to be acquired through this proposed public tender offer to 120,059,970 shares, 77.94% stake, in accordance with Imexpharm Corporation’s foreign ownership cap requirements, and the Company will pay a maximum of VND 6,891,442,278,000. As of March 6, 2026 Livzon Pharmaceutical Group has officially received approval from the State Securities Commission of Vietnam. This allows them to proceed with a voluntary public tender offer for IMP shares. The transaction is subject to approval by merger control clearance, Permissible Foreign Ownership Limit, Absence of Material Adverse Change and other Customary Conditions. The number of shares intended to be sold by the Target Company’s shareholders does not reach the minimum threshold of 99,839,990 shares, representing 64.81% of the Target Company’s charter capital. The expected completion of the transaction is the date falling nine (9) months from the date of the Agreement. The transaction has been approved by the board of directors of Livzon Pharmaceutical Group Inc. Ernst & Young Vietnam Limited acted as due diligence provider to SK Investment Vina III Pte Ltd. Livzon Pharmaceutical Group Inc. (SZSE:000513) completed the acquisition of 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion on April 29, 2026. Shareholders of Livzon Pharmaceutical Group Inc. have reached the minimum threshold of 99,839,990 shares, representing 64.81% of Imexpharm Corporation.
Reported Earnings • Mar 28Full year 2025 earnings: EPS in line with expectations, revenues disappointFull year 2025 results: EPS: ₫1,976 (up from ₫1,791 in FY 2024). Revenue: ₫2.44t (up 11% from FY 2024). Net income: ₫304.4b (up 10% from FY 2024). Profit margin: 13% (in line with FY 2024). Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 9.8% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 09Imexpharm Corporation, Annual General Meeting, Apr 22, 2026Imexpharm Corporation, Annual General Meeting, Apr 22, 2026.
Reported Earnings • Jan 22Full year 2025 earnings: EPS in line with expectations, revenues disappointFull year 2025 results: EPS: ₫1,976 (up from ₫1,932 in FY 2024). Revenue: ₫2.44t (up 11% from FY 2024). Net income: ₫304.4b (up 2.3% from FY 2024). Profit margin: 13% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Oct 23Third quarter 2025 earnings released: EPS: ₫429 (vs ₫436 in 3Q 2024)Third quarter 2025 results: EPS: ₫429. Revenue: ₫573.6b (up 5.3% from 3Q 2024). Net income: ₫76.9b (up 6.2% from 3Q 2024). Profit margin: 13% (in line with 3Q 2024). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia.
Upcoming Dividend • Jun 02Upcoming dividend of ₫500 per shareEligible shareholders must have bought the stock before 09 June 2025. Payment date: 09 July 2025. Payout ratio is a comfortable 30% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Vietnamese dividend payers (8.0%). Lower than average of industry peers (5.6%).
お知らせ • Apr 30Livzon Pharmaceutical Group Inc. (SZSE:000513) acquired 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion.Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 77.94% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6.9 trillion on May 22, 2025. A cash consideration of VND 5.73 trillion will be paid by Livzon Pharmaceutical Group Inc. As part of consideration, VND 5.73 trillion is paid towards common equity of Imexpharm Corporation. The Acquisition will be funded by the Group’s internal resources. The Acquisition will lay a solid foundation for the Group’s further expansion into overseas markets, supporting its long-term strategy of internationalization and sustainable development in the pharmaceutical sector. On December 29, 2025, the parties signed Amendment Agreement to Framework Agreement agreeing to increase the maximum number of shares to be acquired through this proposed public tender offer to 120,059,970 shares, 77.94% stake, in accordance with Imexpharm Corporation’s foreign ownership cap requirements, and the Company will pay a maximum of VND 6,891,442,278,000. As of March 6, 2026 Livzon Pharmaceutical Group has officially received approval from the State Securities Commission of Vietnam. This allows them to proceed with a voluntary public tender offer for IMP shares. The transaction is subject to approval by merger control clearance, Permissible Foreign Ownership Limit, Absence of Material Adverse Change and other Customary Conditions. The number of shares intended to be sold by the Target Company’s shareholders does not reach the minimum threshold of 99,839,990 shares, representing 64.81% of the Target Company’s charter capital. The expected completion of the transaction is the date falling nine (9) months from the date of the Agreement. The transaction has been approved by the board of directors of Livzon Pharmaceutical Group Inc. Ernst & Young Vietnam Limited acted as due diligence provider to SK Investment Vina III Pte Ltd. Livzon Pharmaceutical Group Inc. (SZSE:000513) completed the acquisition of 67.88% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd., Cong Ty Co Phan Dau Tu Binh Minh Kim and KBA Investment joint stock company for VND 6 trillion on April 29, 2026. Shareholders of Livzon Pharmaceutical Group Inc. have reached the minimum threshold of 99,839,990 shares, representing 64.81% of Imexpharm Corporation.
Reported Earnings • Mar 28Full year 2025 earnings: EPS in line with expectations, revenues disappointFull year 2025 results: EPS: ₫1,976 (up from ₫1,791 in FY 2024). Revenue: ₫2.44t (up 11% from FY 2024). Net income: ₫304.4b (up 10% from FY 2024). Profit margin: 13% (in line with FY 2024). Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 9.8% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 09Imexpharm Corporation, Annual General Meeting, Apr 22, 2026Imexpharm Corporation, Annual General Meeting, Apr 22, 2026.
Reported Earnings • Jan 22Full year 2025 earnings: EPS in line with expectations, revenues disappointFull year 2025 results: EPS: ₫1,976 (up from ₫1,932 in FY 2024). Revenue: ₫2.44t (up 11% from FY 2024). Net income: ₫304.4b (up 2.3% from FY 2024). Profit margin: 13% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Oct 23Third quarter 2025 earnings released: EPS: ₫429 (vs ₫436 in 3Q 2024)Third quarter 2025 results: EPS: ₫429. Revenue: ₫573.6b (up 5.3% from 3Q 2024). Net income: ₫76.9b (up 6.2% from 3Q 2024). Profit margin: 13% (in line with 3Q 2024). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia.
Upcoming Dividend • Jun 02Upcoming dividend of ₫500 per shareEligible shareholders must have bought the stock before 09 June 2025. Payment date: 09 July 2025. Payout ratio is a comfortable 30% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Vietnamese dividend payers (8.0%). Lower than average of industry peers (5.6%).
お知らせ • May 22Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 64.81% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd. and others for VND 5.7 trillion.Livzon Pharmaceutical Group Inc. (SZSE:000513) signed Framework Agreement to acquire 64.81% stake in Imexpharm Corporation (HOSE:IMP) from SK Investment Vina III Pte Ltd. and others for VND 5.7 trillion on May 22, 2025. A cash consideration of VND 5.73 trillion will be paid by Livzon Pharmaceutical Group Inc. As part of consideration, VND 5.73 trillion is paid towards common equity of Imexpharm Corporation. The Acquisition will be funded by the Group’s internal resources. The Acquisition will lay a solid foundation for the Group’s further expansion into overseas markets, supporting its long-term strategy of internationalization and sustainable development in the pharmaceutical sector. The transaction is subject to approval by merger control clearance, Permissible Foreign Ownership Limit, Absence of Material Adverse Change and other Customary Conditions. The expected completion of the transaction is the date falling nine (9) months from the date of the Agreement.
Reported Earnings • Apr 19First quarter 2025 earnings released: EPS: ₫448 (vs ₫371 in 1Q 2024)First quarter 2025 results: EPS: ₫448 (up from ₫371 in 1Q 2024). Revenue: ₫594.1b (up 21% from 1Q 2024). Net income: ₫74.5b (up 42% from 1Q 2024). Profit margin: 13% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
New Risk • Mar 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Vietnamese stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Mar 05Imexpharm Corporation, Annual General Meeting, Apr 25, 2025Imexpharm Corporation, Annual General Meeting, Apr 25, 2025.
Reported Earnings • Jan 24Full year 2024 earnings released: EPS: ₫1,932 (vs ₫1,653 in FY 2023)Full year 2024 results: EPS: ₫1,932 (up from ₫1,653 in FY 2023). Revenue: ₫2.21t (up 11% from FY 2023). Net income: ₫320.9b (up 26% from FY 2023). Profit margin: 15% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 29Imexpharm Corporation Appoints Sung Min Woo as Chairperson of the Nomination and Compensation Committee Under the Board of DirectorsImexpharm Corporation announced the Board of Directors' Decision No. 08/2024/QÐ-HÐQT-IMP dated November 27, 2024, regarding the appointment of Mr. Sung Min Woo, Chairperson of the Board of Directors, as the Chairperson of the Nomination and Compensation Committee under the Board of Directors.
Reported Earnings • Oct 22Third quarter 2024 earnings released: EPS: ₫436 (vs ₫404 in 3Q 2023)Third quarter 2024 results: EPS: ₫436 (up from ₫404 in 3Q 2023). Revenue: ₫544.7b (up 17% from 3Q 2023). Net income: ₫72.4b (up 3.9% from 3Q 2023). Profit margin: 13% (down from 15% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 10% per year.
New Risk • Sep 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Vietnamese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Price Target Changed • Aug 23Price target increased by 9.2% to ₫78,485Up from ₫71,861, the current price target is an average from 3 analysts. New target price is 8.1% below last closing price of ₫85,400. Stock is up 46% over the past year. The company is forecast to post earnings per share of ₫4,012 for next year compared to ₫3,307 last year.
Reported Earnings • Jul 23Second quarter 2024 earnings released: EPS: ₫794 (vs ₫851 in 2Q 2023)Second quarter 2024 results: EPS: ₫794 (down from ₫851 in 2Q 2023). Revenue: ₫517.2b (up 18% from 2Q 2023). Net income: ₫65.9b (down 4.8% from 2Q 2023). Profit margin: 13% (down from 16% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 9.4% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 10% per year.
Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₫81,600, the stock trades at a trailing P/E ratio of 26.1x. Average forward P/E is 19x in the Pharmaceuticals industry in Vietnam. Total returns to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₫73,716 per share.
Upcoming Dividend • Jul 05Upcoming dividend of ₫1,000 per shareEligible shareholders must have bought the stock before 11 July 2024. Payment date: 23 July 2024. Payout ratio is a comfortable 27% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Vietnamese dividend payers (8.3%). Lower than average of industry peers (3.4%).
お知らせ • Jul 04Imexpharm Corporation Announces Dividend for the Year 2023, Payable on July 23, 2024Imexpharm Corporation announced Dividend Payout ratio 10% share based on par value (1 share will receive 1,000 VND) for the year 2023. Payment time is July 23, 2024. Ex-right date: July 11, 2024. Record date: July 12, 2024.
Reported Earnings • Apr 23First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: ₫491.1b (up 2.5% from 1Q 2023). Net income: ₫61.9b (up 14% from 1Q 2023). Profit margin: 13% (up from 11% in 1Q 2023).
お知らせ • Mar 27Imexpharm Corporation, Annual General Meeting, Apr 26, 2024Imexpharm Corporation, Annual General Meeting, Apr 26, 2024, at 07:45 SE Asia Standard Time. Location: 5th Floor. Hilton Saigon Hotel, No. 11 Me Unh Square, Ben Nghe Ward, District 1, Ho Chi Minh City Vietnam
Reported Earnings • Jan 21Full year 2023 earnings released: EPS: ₫3,637 (vs ₫2,810 in FY 2022)Full year 2023 results: EPS: ₫3,637 (up from ₫2,810 in FY 2022). Revenue: ₫1.99t (up 21% from FY 2022). Net income: ₫299.6b (up 52% from FY 2022). Profit margin: 15% (up from 12% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
お知らせ • Dec 20Imexpharm Corporation Approves Election of Hoang Duc Hung as an Independent Member of the Board of DirectorsImexpharm Corporation announced that at the General Meeting of Shareholders held on December 19, 2023, approved election of Mr. Hoang Duc Hung as an independent member of the Board of Directors of the Company for the term 2023-2027. Year of birth: 1973, Literacy: Postgraduate. Professional level: Master of International Finance (Oxford Brookes), CIA (IIA), FCCA, FCPA Aust, VACPA. Nationality: Vietnamese. Employment history: From 11/1994 to 06/2014: Audit Director, Leadership of Advisory Services Division, Leadership of the Government and Public Sector Clients Division, Ernst & Young (EY) Vietnam Limited. From 07/2014 to 09/2016: International Consultant - World Bank, supporting the Ministry of Finance in building the Internal audit framework in Vietnam. From 10/2016 to 11/2020: Deputy General Director - PwC Vietnam Limited. From 12/2020 to present: Chairman of the BOD - of CGS Vietnam Governance Consultancy Joint Stock Company; Board Member - Gentis Testing Service Joint Stock Company. From 09/2022 to present: Vice President, Executive Committee Member of Vietnam Independent Directors Association; President of Institute of Internal Auditors Vietnam - IIA Vietnam Chapter. Current positions at other Organizations: President of Institute of Internal Auditors Vietnam - IIA Vietnam Chapter. Vice President, Executive Committee Member of Vietnam Independent Directors Association. Chairman of CGS Vietnam Governance Consultancy Joint Stock Company. Members of BOD of Gentis Testing Service Joint Stock Company. Independent BOD Member of No Va Land Investment Group Corporation.
Reported Earnings • Oct 21Third quarter 2023 earnings released: EPS: ₫889 (vs ₫817 in 3Q 2022)Third quarter 2023 results: EPS: ₫889 (up from ₫817 in 3Q 2022). Revenue: ₫466.9b (up 12% from 3Q 2022). Net income: ₫69.7b (up 25% from 3Q 2022). Profit margin: 15% (up from 13% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 11% per year and the company’s share price has also increased by 11% per year.
Upcoming Dividend • Sep 28Upcoming dividend of ₫1,000 per share at 1.5% yieldEligible shareholders must have bought the stock before 05 October 2023. Payment date: 20 October 2023. Trailing yield: 1.5%. Lower than top quartile of Vietnamese dividend payers (8.8%). Lower than average of industry peers (3.2%).
お知らせ • Sep 19Imexpharm Corporation Announces Dividend, Payable on October 20, 2023Imexpharm Corporation announced Dividend Payout ratio 10% share based on par value (1 share will receive 1,000 VND). Payment time is October 20, 2023.
Upcoming Dividend • Aug 31Upcoming dividend of ₫1,000 per share at 1.5% yieldEligible shareholders must have bought the stock before 07 September 2023. Payment date: 06 October 2023. Trailing yield: 1.5%. Lower than top quartile of Vietnamese dividend payers (8.6%). Lower than average of industry peers (3.2%).
Price Target Changed • Aug 17Price target increased by 14% to ₫84,000Up from ₫73,633, the current price target is provided by 1 analyst. New target price is 20% above last closing price of ₫69,800. Stock is up 10% over the past year. The company is forecast to post earnings per share of ₫4,858 for next year compared to ₫2,951 last year.
Reported Earnings • Jul 20Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: ₫439.7b (up 24% from 2Q 2022). Net income: ₫79.7b (up 66% from 2Q 2022). Profit margin: 18% (up from 14% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia.
お知らせ • May 07Imexpharm Corporation Appoints Chun Chaerhan as Chairperson of the Board of DirectorsImexpharm Corporation at its board meeting held on April 28, 2023, approved the election of Ms. Chun Chaerhan to hold the position of Chairperson of the Board of Directors of the company. The Chairperson of the Board of Directors is responsible for performing her obligations and powers in accordance with the Company's Charter, the Internal Regulations on Governance, the Operating Rules of the Board of Directors, and the provisions of law.
Reported Earnings • Mar 28Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: ₫2,951 (up from ₫2,603 in FY 2021). Revenue: ₫1.64t (up 30% from FY 2021). Net income: ₫196.7b (up 13% from FY 2021). Profit margin: 12% (down from 14% in FY 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 7.4%. Earnings per share (EPS) also surpassed analyst estimates by 1.5%. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 14% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Jan 19Full year 2022 earnings released: EPS: ₫3,495 (vs ₫2,600 in FY 2021)Full year 2022 results: EPS: ₫3,495 (up from ₫2,600 in FY 2021). Revenue: ₫1.64t (up 30% from FY 2021). Net income: ₫234.0b (up 35% from FY 2021). Profit margin: 14% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 14% per year.
Price Target Changed • Jan 04Price target decreased to ₫66,600Down from ₫73,633, the current price target is an average from 2 analysts. New target price is 11% above last closing price of ₫60,200. Stock is down 21% over the past year. The company is forecast to post earnings per share of ₫3,444 for next year compared to ₫2,600 last year.
Valuation Update With 7 Day Price Move • Dec 02Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₫62,500, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 18x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 63% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₫56,442 per share.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Hung Truong was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 21Third quarter 2022 earnings released: EPS: ₫858 (vs ₫413 in 3Q 2021)Third quarter 2022 results: EPS: ₫858 (up from ₫413 in 3Q 2021). Revenue: ₫417.8b (up 63% from 3Q 2021). Net income: ₫55.8b (up 78% from 3Q 2021). Profit margin: 13% (up from 12% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 25Imexpharm Corporation announced that it has received funding from SK Group Ltd.Imexpharm Corporation announced that it has received a round of funding from SK Group Ltd. on August 25, 2022.
Reported Earnings • Jul 23Second quarter 2022 earnings released: EPS: ₫615 (vs ₫684 in 2Q 2021)Second quarter 2022 results: EPS: ₫615. Revenue: ₫354.5b (up 12% from 2Q 2021). Net income: ₫46.6b (up 2.3% from 2Q 2021). Profit margin: 13% (down from 14% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 25%, compared to a 24% growth forecast for the industry in Vietnam.
Price Target Changed • Jul 14Price target increased to ₫79,000Up from ₫73,633, the current price target is an average from 2 analysts. New target price is 27% above last closing price of ₫62,000. Stock is down 15% over the past year. The company is forecast to post earnings per share of ₫3,069 for next year compared to ₫2,600 last year.
お知らせ • Jun 01Imexpharm Corporation Announces Personnel ChangeOn May 25, 2022, Imexpharm Corporation announces the appointment of Mrs. Han Thi Khanh Vinh – member of BOD as Head of Internal Audit Subcommittee and Risk Management Department to replace Mr. Tran Anh Tuan from May 24, 2022.
Upcoming Dividend • May 18Upcoming dividend of ₫1,500 per shareEligible shareholders must have bought the stock before 25 May 2022. Payment date: 24 June 2022. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of Vietnamese dividend payers (7.3%). Lower than average of industry peers (3.6%).
お知らせ • May 14Imexpharm Corporation Announces Cash Dividend for 2021, Payable on June 24, 2022Imexpharm Corporation announced to pay cash dividend for 2021. Exercise ratio: 15.0% (VND 1,500/share). Payment date: June 24, 2022. Ex-right date: May 25, 2022. Record date: May 26, 2022.
Board Change • Apr 27No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 3 experienced directors. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Hung Truong was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Mar 13Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: EPS: ₫2,600 (down from ₫2,773 in FY 2020). Revenue: ₫1.27t (down 7.5% from FY 2020). Net income: ₫173.4b (down 3.5% from FY 2020). Profit margin: 14% (in line with FY 2020). Revenue missed analyst estimates by 9.2%. Earnings per share (EPS) also missed analyst estimates by 12%. Over the next year, revenue is forecast to grow 19%, compared to a 19% growth forecast for the pharmaceuticals industry in Vietnam. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Oct 21Third quarter 2021 earnings released: EPS ₫413 (vs ₫478 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₫256.2b (down 12% from 3Q 2020). Net income: ₫31.3b (down 39% from 3Q 2020). Profit margin: 12% (down from 18% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.
Price Target Changed • Aug 10Price target increased to ₫75,300Up from ₫68,400, the current price target is an average from 3 analysts. New target price is 5.5% above last closing price of ₫71,400. Stock is up 63% over the past year.
Reported Earnings • Jul 23Second quarter 2021 earnings released: EPS ₫651 (vs ₫1,180 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₫317.4b (up 9.9% from 2Q 2020). Net income: ₫49.3b (up 36% from 2Q 2020). Profit margin: 16% (up from 13% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 22% per year.
Upcoming Dividend • Jun 16Upcoming dividend of ₫1,500 per shareEligible shareholders must have bought the stock before 23 June 2021. Payment date: 16 July 2021. Trailing yield: 2.0%. Lower than top quartile of Vietnamese dividend payers (7.5%). Lower than average of industry peers (3.8%).
Reported Earnings • Apr 24First quarter 2021 earnings released: EPS ₫615 (vs ₫564 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: ₫296.4b (down 2.4% from 1Q 2020). Net income: ₫41.0b (up 13% from 1Q 2020). Profit margin: 14% (up from 12% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 19% per year and the company’s share price has also increased by 19% per year.
Reported Earnings • Mar 20Full year 2020 earnings released: EPS ₫2,773 (vs ₫2,225 in FY 2019)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: ₫1.37t (down 2.4% from FY 2019). Net income: ₫179.7b (up 26% from FY 2019). Profit margin: 13% (up from 10% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 20% per year.
Is New 90 Day High Low • Feb 18New 90-day high: ₫60,600The company is up 17% from its price of ₫52,000 on 20 November 2020. The Vietnamese market is also up 17% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫26,735 per share.
Analyst Estimate Surprise Post Earnings • Jan 23Revenue and earnings miss expectationsRevenue missed analyst estimates by 3.2%. Earnings per share (EPS) also missed analyst estimates by 4.4%. Over the next year, revenue is forecast to grow 39%, compared to a 247% growth forecast for the Pharmaceuticals industry in Vietnam.
Reported Earnings • Jan 20Full year 2020 earnings released: EPS ₫2,773The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: ₫1.37t (down 2.4% from FY 2019). Net income: ₫209.7b (up 47% from FY 2019). Profit margin: 15% (up from 10% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Jan 04New 90-day high: ₫58,000The company is up 21% from its price of ₫48,000 on 06 October 2020. The Vietnamese market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫23,764 per share.
Price Target Changed • Dec 23Price target raised to ₫57,910Up from ₫52,663, the current price target is an average from 2 analysts. The new target price is close to the current share price of ₫56,000. As of last close, the stock is up 49% over the past year.
Is New 90 Day High Low • Dec 14New 90-day high: ₫56,800The company is up 15% from its price of ₫49,500 on 15 September 2020. The Vietnamese market is up 16% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫20,200 per share.
Is New 90 Day High Low • Nov 25New 90-day high: ₫54,900The company is up 14% from its price of ₫48,100 on 27 August 2020. The Vietnamese market is also up 14% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫16,865 per share.
Is New 90 Day High Low • Nov 02New 90-day high: ₫49,550The company is up 11% from its price of ₫44,500 on 04 August 2020. The Vietnamese market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₫16,865 per share.
Reported Earnings • Oct 21Third quarter earnings releasedOver the last 12 months the company has reported total profits of ₫180.0b, up 32% from the prior year. Total revenue was ₫1.40t over the last 12 months, up 11% from the prior year.
